Home > Insider Trading > Filing (0001104659-23-122539)

Filing Details

Accession Number:: 0001104659-23-122539
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2023-12-01 06:00:35
Reporting Period:: 2023-11-29

Accepted Time:: 2023-12-01 06:00:35
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1763950	Lantern Pharma Inc.	LTRN	Pharmaceutical Preparations (2834)	463973463

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1813270	Cavu Management, Lp	C/O Lantern Pharma Inc. 1920 Mckinney Avenue, 7Th Floor Dallas TX 75201	No	No	Yes	No
1813310	Cavu Advisors, Llc	C/O Lantern Pharma Inc. 1920 Mckinney Avenue, 7Th Floor Dallas TX 75201	No	No	Yes	No
1813311	Bp Directors, Lp	C/O Lantern Pharma Inc. 1920 Mckinney Avenue, 7Th Floor Dallas TX 75201	No	No	Yes	No
1813316	W. Leslie Kreis	C/O Lantern Pharma Inc. 1920 Mckinney Avenue, 7Th Floor Dallas TX 75201	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2023-11-29	53,640	$3.44	217,553	No	4	S	Indirect	By Bios Fund I QP, LP
Common Stock	Disposition	2023-11-29	91,708	$3.44	371,950	No	4	S	Indirect	By Bios Fund I, LP

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	By Bios Fund I QP, LP
No	4	S	Indirect	By Bios Fund I, LP

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	71,774	Indirect	By Bios Fund II NT, LP
Common Stock	536,163	Indirect	By Bios Fund II QP, LP
Common Stock	164,137	Indirect	By Bios Fund II, LP
Common Stock	26,093	Indirect	By BP Directors, LP

Footnotes

On November 22, 2023, Lantern Pharma Inc. (the "Issuer") purchased 53,640 and 91,708 shares of common stock from Bios Fund I QP, LP ("Bios Fund I QP") and Bios Fund I, LP ("Bios Fund I"), respectively, for an aggregate purchase price of $529,828.80. These purchases were approved by the board of directors of the Issuer.
Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP ("Bios Directors"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of the following entities: Bios Fund II, LP ("Bios Fund II"), Bios Fund II QP, LP ("Bios Fund II QP") and Bios Fund II NT, LP ("Bios Fund II NT"). Cavu Management, LP ("Cavu Management"), an entity managed and controlled by Mr. Kreis, and Bios Capital Management, LP ("Bios Management"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC ("Cavu Advisors"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC ("Bios Advisors"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management.
Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the "Bios Equity Entities"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities.
For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.